CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a neuropathological hallmark of this type of dementia. Currently, the question is unresolved whether CSF levels of P-tau reflect neurofibrillary changes within the brain of a patient with the illness. Twenty-six patients were included with intra-vitam CSF as well as post-mortem neuropathological data. In the CSF, P-tau phosphorylated at threonine 231 (P-tau231P) was analysed. Post-mortem, scores of neurofibrillary tangles (NFT) and neuritic plaques (NP) were assessed in frontal, temporal, parietal and hippocampal cortical areas. In the same cortical regions, load of hyperphosphorylated tau protein (HP-tau load) was determined. Concentrations of P-tau231P were measured in frontal cortex homogenates. We found significant correlations between CSF P-tau231P concentrations and scores of NFTs and HP-tau load in all neocortical regions studied. The score of NPs was correlated with CSF P-tau231P only within the frontal cortex. There was a correlation between P-tau231P in CSF and brain homogenates. These findings indicate that CSF P-tau231P may serve as an in vivo surrogate biomarker of neurofibrillary pathology in Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [81]
In the citing paper
“but correlations between in vivo CSF tau biomarkers and tau aggregates in postmortem tissue are weaker (11).”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [11]
In the citing paper
“levels of CSF tau and phosphorylated tau (ptau) species are elevated in DAT8, 13, 14 and are hypothesized to reflect the presence of neurofibrillary tangles and/or neurodegeneration,15, 16 although not all studies support this conclusion.17”
From Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly (2009) · cites this paper as [16]
Citations
Cites
Efron, B., & Tibshirani, R. (1986) · Statistical Science · doi:10.1214/ss/1177013815 · Cited by 6,033
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Self-citationGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 2×
“A staging system of Alzheimer’s-associated neurofibrillary pathology using immunohistochemistry and AT8 has been suggested (Braak et al., 2006).”
BackgroundMethodSelf-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 2×
“Whereas NFTs and neuritic processes are composed of fibrils containing phosphorylated tau, plaques consist mostly of fibrillous beta-amyloid (Grundke-Iqbal et al., 1986; Lee et al., 1991; Dickson, 1997).”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 4×
“CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease Katharina Buerger,1,* Michael Ewers,1,* Tuula Pirttilä,2 Raymond Zinkowski,4 Irina Alafuzoff,3 Stefan J. Teipel,1 John DeBernardis,4 Daniel Kerkman,4 Cheryl McCulloch,4 Hilkka Soininen2 and Harald Hampel1 1Deme…”
BackgroundMethodResultInfluentialSelf-citationConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Mandelkow, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01368-3 · Cited by 953
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Cited by
Items 301–400 of 584
Cicognola, C., Chiasserini, D., & Parnetti, L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00143 · Cited by 35
Biomarkers in Alzheimer’s Disease
Riverol, M., & López, O. L. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00046 · Cited by 37
Souza, L. C. D., Bertoux, M., Funkiewiez, A., Samri, D., Azuar, C., Habert, M.-O., Kas, A., Lamari, F., Sarazin, M., & Dubois, B. (2013) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642013dn70100011 · Cited by 31
Sun, Y., Lin, J., & Zhang, L. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.12.59 · Cited by 38
Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology
Kalyaanamoorthy, S., Opare, S. K. A., Xu, X., Ganesan, A., & Rao, P. P. N. (2024) · Current Alzheimer Research · doi:10.2174/0115672050301407240408033046 · Cited by 32
Use of Biomarkers in Clinical Trials of Alzheimer Disease: From Concept to Application
Wu, L., Rosa‐Neto, P., & Gauthier, S. G. (2011) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256467 · Cited by 34
Flunkert, S., Hierzer, M., Löffler, T., Rabl, R., Neddens, J., Duller, S., Schofield, E., Ward, M. A., Posch, M., Jungwirth, H., et al. (2012) · Neurodegenerative Diseases · doi:10.1159/000338152 · Cited by 36
Ba, M., Li, X., Ng, K. P., Pascoal, T. A., Mathotaarachchi, S. S., Rosa‐Neto, P., Gauthier, S. G., & Initiative, A. D. N. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.005 · Cited by 39
Amyloid-β as a biomarker for Alzheimer’s disease: quantification methods in body fluids
Galozzi, S., Marcus, K., & Barkovits, K. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1065183 · Cited by 32
Chakraborty, A., Chatterjee, M., Twaalfhoven, H. A. M., del Campo, M., Teunissen, C. E., Scheltens, P., Fontijn, R. D., van der Flier, W. M., & de Vries, H. E. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0385-8 · Cited by 32
Clinical Investigations in Primary Care
de Souza, L. C., Sarazin, M., Goetz, C., & Dubois, B. (2009) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000197897 · Cited by 33
Brunnström, H., Hansson, O., Zetterberg, H., Londos, E., & Englund, E. M. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3881 · Cited by 31
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 34
Weiler, M., de Campos, B. M., Teixeira, C. V. L., Casseb, R. F., Carletti‐Cassani, A. F. M. K., Vicentini, J. E., Magalhães, T. N. C., Talib, L. L., Forlenza, O. V., & Balthazar, M. L. F. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160190 · Cited by 29
Khan, M. H.-M., Reesaul, P., Auzine, M. M., & Taylor, A. (2024) · Artificial Intelligence Review · doi:10.1007/s10462-024-10914-z · Cited by 37
Genius, J., Klafki, H., Benninghoff, J., Esselmann, H., & Wiltfang, J. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0362-3 · Cited by 31
Qin, Q., Wan, H., Wang, D., Li, J., Qu, Y., Zhao, J., Li, J., & Xue, Z. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.892493 · Cited by 31
Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes
Hohman, T. J., Samuels, L. R., Liu, D., Gifford, K. A., Mukherjee, S., Benson, E. M., Abel, T. W., Ruberg, F. L., & Jefferson, A. L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.021 · Cited by 31
Alzheimer disease: From biomarkers to diagnosis
Dubois, B., Epelbaum, S., Santos, A., Stefano, F. D., Julian, A. G., Michon, A., Sarazin, M., & Hampel, H. J. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.016 · Cited by 35
Self-citationAutoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer’s Disease
Giil, L. M., Kristoffersen, E. K., Vedeler, C. A., Aarsland, D., Nordrehaug, J. E., Winblad, B. G., Cedazo-Mínguez, Á., Lund, A., & Reksten, T. R. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150053 · Cited by 30
Sjödin, S., Hansson, O., Öhrfelt, A., Brinkmalm, G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2017) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201700100 · Cited by 29
Leko, M. B., Willumsen, N., Perković, M. N., Klepac, N., Borovečki, F., Hof, P. R., Sonicki, Z., Pivac, N., de Silva, R., & Šimić, G. (2018) · Brain and Behavior · doi:10.1002/brb3.1128 · Cited by 27
Jacob, M. E., O’Donnell, A., Samra, J. K., Gonzales, M. M., Satizábal, C. L., Pase, M. P., Murabito, J. M., Beiser, A., & Seshadri, S. S. (2022) · The Journal of Frailty & Aging · doi:10.14283/jfa.2022.17 · Cited by 33
Li, Z., Fan, Z., & Zhang, Q. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230799 · Cited by 30
Maldonado, H., Ramírez, E., V, Utreras, E., Pando, M. E., Kettlun, A. M., Chiong, M., Kulkarni, A. B., Collados, L., Puente, J., Cartier, L., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22678 · Cited by 31
Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Stella, F., & Gattaz, W. F. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2012-3505 · Cited by 33
Furr, J. W., Morales‐Scheihing, D., Manwani, B., Lee, J., & McCullough, L. D. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08568-0 · Cited by 29
Phospholipid transfer protein reduces phosphorylation of tau in human neuronal cells
Dong, W., Albers, J. J., & Vuletic, S. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22137 · Cited by 30
Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum
Lee, J., Jang, H., Kang, S. H., Kim, J., Kim, J. S., Kim, J. P., Kim, H. J., Seo, S. W., & Na, D. L. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e361 · Cited by 27
Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer’s Disease Diagnosis
Cui, Y., Zhang, H., Zhu, J., Liao, Z., Wang, S., & Liu, W. (2022) · Brain Sciences · doi:10.3390/brainsci12050595 · Cited by 34
Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease
Susmitha, G., & Kumar, R. K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109478 · Cited by 28
Santos, J. R. F., Bauer, C., Schuchhardt, J., Wedekind, D., Waniek, K., Lachmann, I., Wiltfang, J., & Vogelgsang, J. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01982-5 · Cited by 26
Baghel, V., Tripathi, M., Parida, G. K., Gupta, R., Yadav, S., Kumar, P., Dey, A. B., Damle, N. A., Kumar, R., & Bal, C. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002791 · Cited by 26
Distinct Neurotoxic Effects of Extracellular Tau Species in Primary Neuronal-Glial Cultures
Pampuščenko, K., Morkūnienė, R., Krasauskas, L., Smirnovas, V., Tomita, T., & Borutaitė, V. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02150-7 · Cited by 32
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
Pawlowski, M., Meuth, S., & Duning, T. (2017) · Diagnostics · doi:10.3390/diagnostics7030042 · Cited by 25
Provost, K., Iaccarino, L., Soleimani‐Meigooni, D. N., Baker, S. L., Edwards, L., Eichenlaub, U., Hansson, O., Jagust, W. J., Janabi, M., Joie, R. L., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05152-8 · Cited by 27
Onset of Preclinical Alzheimer Disease in Monozygotic Twins
Konijnenberg, E., Tomassen, J., den Braber, A., ten Kate, M., Yaqub, M. M., Mulder, S. D., Nivard, M. G., Vanderstichele, H., Lammertsma, A. A., Teunissen, C. E., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26048 · Cited by 27
Kumar, A., Nemeroff, C. B., Cooper, J. J., Widge, A. S., Rodríguez, C. I., Carpenter, L. L., & McDonald, W. M. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.19080873 · Cited by 25
Keith, C. M., Haut, M. W., Wilhelmsen, K. C., Mehta, R. I., Miller, M. D., Navia, R. O., Ward, M., Lindberg, K. E., Coleman, M., McCuddy, W. T., et al. (2022) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2022.2144618 · Cited by 27
An overview of biomarkers in Alzheimer′s disease
Mathuranath, P. S., & Wattamwar, P. R. (2010) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.74256 · Cited by 31
Could Clinical Profile Influence CSF Biomarkers in Early-onset Alzheimer Disease?
Koric, L., Félician, O., Guedj, É., Hubert, A.-M., Mancini, J., Boucraut, J., & Ceccaldi, M. P. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181d712d9 · Cited by 27
Cerebrospinal fluid biomarkers of β‐amyloid metabolism and neuronal damage in epileptic seizures
Shahim, P., Ręjdak, R., Książek, P., Blennow, K., Zetterberg, H., Mattsson, N., & Rejdak, K. (2013) · European Journal of Neurology · doi:10.1111/ene.12336 · Cited by 27
Hertze, J., Palmqvist, S., Minthon, L., & Hansson, O. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000348353 · Cited by 25
Shahim, P., Blennow, K., Johansson, P., Svensson, J., Lista, S., Hampel, H. J., Andersson, L. C., & Zetterberg, H. (2016) · NeuroMolecular Medicine · doi:10.1007/s12017-016-8439-1 · Cited by 27
Self-citationNavale, G. R., Ahmed, I., Lim, M. H., & Ghosh, K. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401991 · Cited by 26
Yamamori, H., Khatoon, S., Grundke, I., Blennow, K., Ewers, M., Hampel, H. J., & Iqbal, K. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.03.022 · Cited by 24
Self-citationHata, M., Tanaka, T., Kazui, H., Ishii, R., Canuet, L., Pascual-Marqui, R. D., Aoki, Y., Ikeda, S., Sato, S., Suzuki, Y., et al. (2016) · Clinical EEG and Neuroscience · doi:10.1177/1550059416662119 · Cited by 26
Wei, J., Qiu, Z., Yu, D., Yin, Y., Tang, Q., Liao, X., Zhang, G., Liu, Z., & Gao, F. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133656 · Cited by 24
Tau Monoclonal Antibody Generation Based on Humanized Yeast Models
Rosseels, J., den Brande, J. V., Violet, M., Jacobs, D., Grognet, P., Lopez, J. M., Huvent, I., Caldara, M., Swinnen, E., Papegaey, A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.627919 · Cited by 27
Park, S. M., & Kim, K. S. (2013) · Prion · doi:10.4161/pri.22850 · Cited by 26
Benvenutto, A., Giusiano, B., Koric, L., Guériot, C., Didic, M., Félician, O., Guye, M., Guedj, É., & Ceccaldi, M. P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180292 · Cited by 25
Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions
Taghdiri, F., Multani, N., Tarazi, A., Naeimi, S. A., Khodadadi, M., Esopenko, C., Green, R., Colella, B., Wennberg, R. A., Mikulis, D. J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007608 · Cited by 29
Idland, A., Sala‐Llonch, R., Watne, L. O., Brækhus, A., Hansson, O., Blennow, K., Zetterberg, H., Sørensen, Ø., Walhovd, K. B., Wyller, T. B., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.04.002 · Cited by 23
Klafki, H., Lewczuk, P., Kamrowski‐Kruck, H., Maler, J. M., Müller, K., Peters, O., Heuser, I., Jessen, F., Popp, J., Frölich, L., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1167 · Cited by 23
Neuropathology‐based APOE genetic risk score better quantifies Alzheimer's risk
Deming, Y. K., Vasiljevic, E., Morrow, A. R., Miao, J., Hulle, C. V., Jonaitis, E. M., Ma, Y., Whitenack, V. M., Kollmorgen, G., Wild, N., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12990 · Cited by 23
Zetterberg, H., Lautner, R., Skillbäck, T. B., Rosén, C., Shahim, P., Mattsson, N., & Blennow, K. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800141-7.00005-x · Cited by 25
Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies
McKenzie-Nickson, S., Chan, J., Perez, K. A., Hung, L. W., Cheng, L., Sedjahtera, A., Gunawan, L., Adlard, P. A., Hayne, D. J., McInnes, L. E., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00161 · Cited by 24
Cao, L., Guan, P.-P., Liang, Y.-Y., Huang, X., & Wang, P. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181066 · Cited by 22
Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease
Carapelle, E., Mundi, C., Cassano, T., & Avolio, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176279 · Cited by 23
Malpas, C. B., Initiative, A. D. N., Saling, M. M., Velakoulis, D., Desmond, P. M., & O'Brien, T. J. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142643 · Cited by 23
Kotarba, S., Kozłowska, M., Scios, M., Saramowicz, K., Barczuk, J., Granek, Z., Siwecka, N., Wiese, W., Golberg, M., Galita, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910797 · Cited by 26
Protein and Imaging Biomarkers in the Eye for Early Detection of Alzheimer’s Disease
Fereshetian, S., Agranat, J. S., Siegel, N. H., Ness, S. D., Stein, T. D., & Subramanian, M. L. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210283 · Cited by 26
Risk factors of cognitive impairment: Impact of decline in oral function
Takahashi, T., Hatta, K., & Ikebe, K. (2023) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2023.06.006 · Cited by 24
Utility of imaging for nutritional intervention studies in Alzheimer's disease
de Wilde, M. C., Kamphuis, P. J. G. H., Sijben, J., & Scheltens, P. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.07.011 · Cited by 22
Brinkmalm, A., Portelius, E., Brinkmalm, G., Pannee, J., Dahlén, R., Gobom, J., Blennow, K., & Zetterberg, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14594 · Cited by 23
Avdoshina, V., Mahoney, M., Gilmore, S. F., Wenzel, E. D., Anderson, A. M. L., Letendre, S. L., Imamichi, T., Fischer, N. O., & Mocchetti, I. (2020) · AIDS · doi:10.1097/qad.0000000000002509 · Cited by 23
Biofluid Biomarkers of Mild Traumatic Brain Injury: Whither Plasma Tau
Peskind, E. R., Kraemer, B. C., & Zhang, J. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1789 · Cited by 24
The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer’s Disease
Engelborghs, S., & Bastard, N. L. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/bf03262201 · Cited by 20
Arastoo, M., Lofthouse, R. A., Penny, L. K., Harrington, C. R., Porter, A., Wischik, C. M., & Palliyil, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228673 · Cited by 21
Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use
George, N., Gean, E. G., Nandi, A., Фролов, Б. А., Zaidi, E., Lee, H., Brašić, J. R., & Wong, D. F. (2015) · CNS Drugs · doi:10.1007/s40263-015-0237-z · Cited by 24
Genetic modification of the relationship between phosphorylated tau and neurodegeneration
Hohman, T. J., Koran, M. E. I., Thornton‐Wells, T. A., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.022 · Cited by 23
Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy
Heier, M., Skinningsrud, A., Paus, E., & Gautvik, K. M. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.02.005 · Cited by 20
Molinuevo, J. L., Minguillón, C., Rami, L., & Gispert, J. D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170698 · Cited by 25
Ihara, R., Iwata, A., Suzuki, K., Ikeuchi, T., Kuwano, R., Iwatsubo, T., & Initiative, J. A. D. N. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.004 · Cited by 25
van Hooren, R. W. E., Verhey, F. R. J., Ramakers, I. H. G. B., Jansen, W. J., & Jacobs, H. I. L. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.024 · Cited by 22
Fagan, A. M. (2014) · Advances in Geriatrics · doi:10.1155/2014/302712 · Cited by 25
Leko, M. B., Perković, M. N., Klepac, N., Štrac, D. Š., Borovečki, F., Pivac, N., Hof, P. R., & Šimić, G. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190991 · Cited by 22
Identification of cis-acting determinants mediating the unconventional secretion of tau
Katsinelos, T., McEwan, W. A., Jahn, T. R., & Nickel, W. (2021) · Scientific Reports · doi:10.1038/s41598-021-92433-3 · Cited by 19
Park, S. A., Kang, J.-H., Kang, E., Ki, C., Roh, J. H., Youn, Y. C., Kim, S. Y., & Kim, S. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.2.132 · Cited by 22
Clinical indications for analysis of Alzheimer's disease CSF biomarkers
Engelborghs, S. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.024 · Cited by 22
Enfermedad de Alzheimer. Guía de práctica clínica
Allegri, R., Arizaga, R. L., Bavec, C. V., Colli, L. P., Demey, I., Fernández, M. C., Frontera, S. A., Garau, M. L., Jiménez, J. J., Golimstok, Á., et al. (2011) · Neurología Argentina · doi:10.1016/s1853-0028(11)70026-x · Cited by 53
Towards New Therapies for Parkinson's Disease
Finkelstein, D. I. (2011) · InTech eBooks · doi:10.5772/954 · Cited by 19
Zhao, S., Rangaprakash, D., Venkataraman, A., Liang, P., & Deshpande, G. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00211 · Cited by 23
Mazzeo, S., Lassi, M., Padiglioni, S., Vergani, A. A., Moschini, V., Scarpino, M., Giacomucci, G., Burali, R., Morinelli, C., Fabbiani, C., et al. (2023) · BMC Neurology · doi:10.1186/s12883-023-03347-8 · Cited by 23
Biomarkers of Alzheimer's disease: The present and the future
Lehmann, S., Delaby, C., Touchon, J., Hirtz, C., & Gabelle, A. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.012 · Cited by 20
Leclerc, B., & Abulrob, A. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/589308 · Cited by 28
Biomarkers for Alzheimer’s disease
Sonnen, J. A., Keene, C. D., Montine, K. S., Li, G., Peskind, E. R., Zhang, J., & Montine, T. J. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.8.1021 · Cited by 19
Zhong, S., Zhao, B., Ma, Y.-H., Sun, Y., Zhao, Y.-L., Liu, W.-H., Ou, Y.-N., Dong, Q., Tan, L., & Yu, J.-T. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220389 · Cited by 14
Tau: a biomarker of Huntington’s disease
Lepinay, E., & Cicchetti, F. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02230-9 · Cited by 19
Novel Biomarkers for Alzheimer’s Disease: Plasma Neurofilament Light and Cerebrospinal Fluid
Abukuri, D. N. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/6668159 · Cited by 32
Neergaard, J. S., Dragsbæk, K., Christiansen, C., Karsdal, M. A., Brix, S., & Henriksen, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194802 · Cited by 17
Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ42/40 ratio
Pouclet‐Courtemanche, H., Nguyen, T., Skrobala, E., Boutoleau‐Bretonnière, C., Pasquier, F., Bouaziz-Amar, É., Bigot‐Corbel, E., Schraen‐Maschke, S., Dumurgier, J., Paquet, C., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.001 · Cited by 19
Biochemical Markers in Alzheimer's Disease Clinical Trials
Zetterberg, H., Mattsson, N., Shaw, L. M., & Blennow, K. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.80 · Cited by 22
Illustrated Neuropathologic Diagnosis of Alzheimer’s Disease
Doher, N., Davoudi, V., Magaki, S., Townley, R. A., Haeri, M., & Vinters, H. V. (2023) · Neurology International · doi:10.3390/neurolint15030054 · Cited by 16
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
Zetterberg, H., Mattsson, N., Blennow, K., & Olsson, B. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt56 · Cited by 16
Tau protein in cerebrospinal fluid: a novel biomarker of the time of death?
Peyron, P., Hirtz, C., Baccino, É., Ginestet, N., Tiers, L., Yahiaoui-Martinez, A., Lehmann, S., & Delaby, C. (2021) · International Journal of Legal Medicine · doi:10.1007/s00414-021-02558-3 · Cited by 17
Uncovering tau in wasteosomes (corpora amylacea) of Alzheimer’s disease patients
Riba, M., del Valle, J., Romera, C., Alsina, R., Molina‐Porcel, L., Pelegrí, C., & Vilaplana, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1110425 · Cited by 16
Smith, R. G., Pishva, E., Kouhsar, M. P., Imm, J. L., Dobričić, V., Johannsen, P., Wittig, M., Franke, A., Vandenberghe, R. R., Schaeverbeke, J. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14098 · Cited by 17
Giacomucci, G., Mazzeo, S., Bagnoli, S., Casini, M., Padiglioni, S., Polito, C., Berti, V., Balestrini, J., Ferrari, C., Lombardi, G., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11010047 · Cited by 18
Role of triggering receptor expressed on myeloid cells 2 (TREM2) in neurodegenerative dementias
Shafi, S., Singh, A., Ibrahim, A. M., Alhajri, N., Izneid, T. A., & Pottoo, F. H. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15215 · Cited by 15
Metadata
- Authors
- Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., & Hampel, H.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Kuopio University Hospital (FI)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09-29
- Volume
- 129
- Issue
- 11
- Pages
- 3035-3041
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2145450560
- Cited by
- 586
- References
- 33
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 23 · 2023: 21 · 2022: 26 · 2021: 38 · 2020: 40 · 2019: 44 · 2018: 34 · 2017: 31 · 2016: 27 · 2015: 39 · 2014: 34 · 2013: 33 · 2012: 43
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, p-tau231, cerebrospinal fluid biomarkers, neurofibrillary tangles, neuritic plaques, neocortex, frontal cortex, hippocampus, postmortem neuropathology
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Frontal Lobe, Hippocampus, Humans, Male, Parietal Lobe, Phosphorylation, Temporal Lobe, Biomarkers, Neurofibrillary Tangles, tau Proteins, Neocortex, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.